Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 6/20 | 0.64 |
| ▸ | RXRB | P28702 | 6/20 | 0.64 |
| ▸ | RXRG | P48443 | 6/20 | 0.64 |
| ▸ | MRGPRX4 | Q96LA9 | 7/20 | 0.64 |
| ▸ | PTGER1 | P34995 | 5/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14925356 | 0.90 | RXRA (0.55) | RXRARXRBRXRGMRGPRX4PTGER1 | |
| SCHEMBL536554 | 0.86 | TSHR (0.51) | RXRARXRBRXRGMRGPRX4POLB | |
| SCHEMBL849231 | 0.85 | RXRA (0.72) | RXRARXRBRXRGMRGPRX4PTGER1 | |
| SCHEMBL10035090 | 0.83 | PTGDR2 (0.52) | RXRARXRBRXRGMRGPRX4POLB | |
| SCHEMBL79709 | 0.83 | RXRA (0.72) | RXRARXRBRXRGMRGPRX4PTGER1 | |
| SCHEMBL5786405 | 0.82 | AKR1C3 (0.55) | RXRARXRBRXRGMRGPRX4 | |
| SCHEMBL3798678 | 0.80 | RXRA (0.71) | RXRARXRBRXRGMRGPRX4PTGER1 | |
| SCHEMBL10035086 | 0.80 | ALDH1A1 (0.54) | RXRARXRBRXRGMRGPRX4 | |
| SCHEMBL272324 | 0.79 | PTPRC (0.54) | RXRARXRBRXRGMRGPRX4POLB | |
| SCHEMBL22480756 | 0.78 | MRGPRX4 (1.00) | RXRARXRBRXRGMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130116227-A1 | BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116227-A1 | BIARYL AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | MC2R, NR3C2, REN | RXRA 824/4885RXRB 849/4885RXRG 1171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.